UPR vs. PRTC, AMS, CRW, MXCT, BMK, OXB, NIOX, ONT, BVXP, and TSTL
Should you be buying Uniphar stock or one of its competitors? The main competitors of Uniphar include PureTech Health (PRTC), Advanced Medical Solutions Group (AMS), Craneware (CRW), MaxCyte (MXCT), Benchmark (BMK), Oxford Biomedica (OXB), NIOX Group (NIOX), Oxford Nanopore Technologies (ONT), Bioventix (BVXP), and Tristel (TSTL). These companies are all part of the "medical" sector.
Uniphar (LON:UPR) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability.
PureTech Health received 524 more outperform votes than Uniphar when rated by MarketBeat users. However, 100.00% of users gave Uniphar an outperform vote while only 86.58% of users gave PureTech Health an outperform vote.
In the previous week, Uniphar's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.
50.4% of Uniphar shares are held by institutional investors. Comparatively, 80.0% of PureTech Health shares are held by institutional investors. 10.1% of Uniphar shares are held by insiders. Comparatively, 14.6% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Uniphar has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.
Uniphar has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.
Uniphar has a net margin of 1.75% compared to PureTech Health's net margin of 0.00%. Uniphar's return on equity of 14.48% beat PureTech Health's return on equity.
Summary
Uniphar beats PureTech Health on 8 of the 13 factors compared between the two stocks.
Get Uniphar News Delivered to You Automatically
Sign up to receive the latest news and ratings for UPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
